Baidu
map

ASCO 2016 :糖尿病药物二甲双胍或可有效预防并治疗乳腺癌

2016-06-05 佚名 生物谷

近日,一项发表于美国临床肿瘤学会年会上的研究报告中,来自宾夕法尼亚大学的研究人员通过研究发现,常用作2型糖尿病一线疗法的药物二甲双胍或可改善某些乳腺癌患者的生存,同时其还可作为治疗子宫内膜增生症患者的潜在疗法。 在其中一项研究中,研究人员首先检测了二甲双胍的治疗对乳腺癌患者生存率的影响,研究者对在1997年至2013年间诊断为乳腺癌或者进行手术疗法的1215名患者进行了相应的临床试验并且检测

近日,一项发表于美国临床肿瘤学会年会上的研究报告中,来自宾夕法尼亚大学的研究人员通过研究发现,常用作2型糖尿病一线疗法的药物二甲双胍或可改善某些乳腺癌患者的生存,同时其还可作为治疗子宫内膜增生症患者的潜在疗法(EBCC 10:糖尿病的治疗是如何影响乳腺密度的?)(Lancet:石远凯谈糖尿病与癌症的错综关系)。

在其中一项研究中,研究人员首先检测了二甲双胍的治疗对乳腺癌患者生存率的影响,研究者对在1997年至2013年间诊断为乳腺癌或者进行手术疗法的1215名患者进行了相应的临床试验并且检测了患者的临床治疗效果,其中97名患者在诊断前利用二甲双胍进行治疗,而另外97名患者在诊断后利用二甲双胍进行治疗。

结果表明,相比不服用二甲双胍的患者而言,在乳腺癌诊断前摄入二甲双胍的患者死亡的可能性是前者的2倍,而当患者诊断为乳腺癌后使用二甲双胍进行治疗,则死亡的可能性大约是不服用二甲双胍患者50%。医学博士Yun Rose Li说道,利用二甲双胍作为癌症预防措施目前仍然存在争议,而且很多研究结果并不一致,我们在研究中发现,二甲双胍和使用时间存在明显关联,这或许就可以解释很多研究所得结果不一致的问题了。研究人员发现,使用二甲双胍可以明显改善某些乳腺癌患者的存活率(Obstet Gynecol :研究证实二甲双胍具有抗肿瘤作用)。

在额外的研究中,研究者发现,使用二甲双胍的个体可能更多都是50岁以上被诊断出乳腺癌的患者或非洲裔美国个体,所有研究对象机体中的肿瘤尺寸和疾病进展程度都类似,在诊断为乳腺癌后进行二甲双胍治疗的患者更易于出现ER/PR阳性的肿瘤,而在诊断前进行二甲双胍治疗的患者而患HER2+及三阴性乳腺癌的风险则较高。

上述研究中,研究人员首次检测了长期使用二甲双胍对于治疗乳腺癌患者的效应。而在第二项研究中,研究者则检测了二甲双胍治疗子宫内膜增生症患者的效应,子宫内膜增生症的发生往往是患者机体激素失衡引发的子宫内膜组织的异常生长导致的,如果子宫内膜增生症不进行治疗,患者就会患高风险的子宫癌。

研究者招募了18名患者,利用二甲双胍对患者连续治疗三个月,结果表明,56%的患者对疗法产生了反应,可以认为这些患者的病情完全治愈了,同样地,研究者也在单纯性增生的患者中也发现了二甲双胍的相似治疗效应。研究者Emily Ko表示,研究结果或为子宫内膜增生症患者提供了一种特殊的疗法,在未来的前瞻性研究中,我们还将继续深入研究来寻找哪些患者会因二甲双胍的治疗而获益,并且制定出最有效的二甲双胍剂量使用体系。

但是,此前也有一些研究不支持相似的结论(Diabetes Care:二甲双胍或不能改善糖尿病合并乳腺癌患者的生存

原始出处:

Diabetes drug metformin holds promise for cancer treatment and prevention

更多ASCO 2016的最新内容,请点击此处进入“ASCO 2016”专题。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1938559, encodeId=9d8c193855914, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jul 31 09:16:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88929, encodeId=5ed98892926, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Tue Jun 07 07:40:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584076, encodeId=b2a315840e6c2, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88771, encodeId=5e5288e7132, content=精品文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:08:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88772, encodeId=6d7088e7281, content=已经收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:08:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88770, encodeId=210f88e7046, content=这个厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:07:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88605, encodeId=8a4b886053f, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:05:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-07-31 quxin068
  2. [GetPortalCommentsPageByObjectIdResponse(id=1938559, encodeId=9d8c193855914, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jul 31 09:16:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88929, encodeId=5ed98892926, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Tue Jun 07 07:40:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584076, encodeId=b2a315840e6c2, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88771, encodeId=5e5288e7132, content=精品文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:08:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88772, encodeId=6d7088e7281, content=已经收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:08:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88770, encodeId=210f88e7046, content=这个厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:07:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88605, encodeId=8a4b886053f, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:05:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-07 yde2801fm***3926(暂无匿称)

    多多学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1938559, encodeId=9d8c193855914, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jul 31 09:16:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88929, encodeId=5ed98892926, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Tue Jun 07 07:40:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584076, encodeId=b2a315840e6c2, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88771, encodeId=5e5288e7132, content=精品文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:08:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88772, encodeId=6d7088e7281, content=已经收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:08:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88770, encodeId=210f88e7046, content=这个厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:07:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88605, encodeId=8a4b886053f, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:05:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1938559, encodeId=9d8c193855914, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jul 31 09:16:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88929, encodeId=5ed98892926, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Tue Jun 07 07:40:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584076, encodeId=b2a315840e6c2, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88771, encodeId=5e5288e7132, content=精品文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:08:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88772, encodeId=6d7088e7281, content=已经收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:08:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88770, encodeId=210f88e7046, content=这个厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:07:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88605, encodeId=8a4b886053f, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:05:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-06 milkshark

    精品文章

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1938559, encodeId=9d8c193855914, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jul 31 09:16:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88929, encodeId=5ed98892926, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Tue Jun 07 07:40:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584076, encodeId=b2a315840e6c2, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88771, encodeId=5e5288e7132, content=精品文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:08:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88772, encodeId=6d7088e7281, content=已经收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:08:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88770, encodeId=210f88e7046, content=这个厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:07:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88605, encodeId=8a4b886053f, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:05:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-06 milkshark

    已经收藏

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1938559, encodeId=9d8c193855914, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jul 31 09:16:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88929, encodeId=5ed98892926, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Tue Jun 07 07:40:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584076, encodeId=b2a315840e6c2, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88771, encodeId=5e5288e7132, content=精品文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:08:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88772, encodeId=6d7088e7281, content=已经收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:08:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88770, encodeId=210f88e7046, content=这个厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:07:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88605, encodeId=8a4b886053f, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:05:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-06 milkshark

    这个厉害

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1938559, encodeId=9d8c193855914, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jul 31 09:16:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88929, encodeId=5ed98892926, content=多多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Tue Jun 07 07:40:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584076, encodeId=b2a315840e6c2, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Tue Jun 07 02:16:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88771, encodeId=5e5288e7132, content=精品文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:08:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88772, encodeId=6d7088e7281, content=已经收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:08:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88770, encodeId=210f88e7046, content=这个厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 07:07:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88605, encodeId=8a4b886053f, content=不错的文章,多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:05:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-05 沉心多思

    不错的文章,多学习

    0

相关资讯

CA Cancer J Clin:美国肿瘤幸存者人数逐年增加

近年来男性和女性的癌症发病率稳步下降,癌症幸存者的数量逐年增加。主要原因包括早期发现和治疗方式有效,此外还包括生活质量的提高使得人们寿命更长和人口基数增加。 研究人员指出,尽管人们对生命的认识程度得以提高,但是民众仍然面临许多严峻的挑战。该研究旨在分析当前癌症幸存者的数量和预测水平,研究结果发表在CA: A Cancer Journal for Clinicians。2016年常见癌症男性幸存者人

BMJ研究新闻:健康的生活方式可降低乳腺癌高危女性的发病风险

据美国一项新的研究表明,存在乳腺癌遗传因素、家族史及生育史的乳腺癌高危女性若遵循健康的生活方式则其乳腺癌的发生风险与不存在这些不可变危险因素的女性类似。研究共纳入了17171名乳腺癌患者和19862名参与乳腺癌和前列腺癌的队列合作联盟的对照者,以及5879名参加美国健康调查的女性,以开发一个可预测乳腺癌发病风险的模型。研究人员从个人层面上组合了关于危险因素的数据,如年龄、体重、吸烟状况,以及关于9

警告:少量饮酒也会增加女性患乳腺癌风险!

法国里昂癌症研究机构(IARC)的Kevin D. Shield博士和同事指出,少量饮酒增加女性患乳腺癌的风险,研究结果发表在Alcoholism: Clinical and Experimental Research。这一研究结论解决了关于少量饮酒与乳腺癌风险的长期争论。1987年IARC正式宣布口腔、咽部、喉部、食道等位置的肿瘤与肝癌的发生与饮酒有直接关系。自那时以来,许多研究发现饮酒与乳腺癌

Breast Cancer Res:福音!他汀类药物或可有效治疗雌激素受体阳性的乳腺癌女性

近日,来自伦敦大学癌症研究学院的研究人员发现,乳腺癌细胞产生一种模仿雌激素的分子,因此他们呼吁进行临床试验以探究他汀类药物对复发性乳腺癌患者的治疗效果,该研究成果已发表于Breast Cancer Research。在英国,每年有多达4万名女性诊断为雌激素受体(ER)阳性乳腺癌,很多患者术后服用他莫昔芬或芳香酶抑制剂来阻断雌激素的作用,并降低疾病的复发风险。但是,即使是经过内分泌治疗仍有约1.2 

Cell Res:RANKL抑制剂有望预防乳腺癌的发生

大约8名女性中就有一人将在她的一生当中患上浸润性乳腺癌。这可能是使用人工合成性激素和其他环境因子导致的,也可能是BRCA1基因等发生突变导致的。平均而言,BRCA1基因发生突变的女性有高达87%的风险患上乳腺癌。截至目前,预防性手术切除是显著降低乳腺癌风险的唯一方法,但是这也经常伴随着术后并发症。 2010年,奥地利科学院分子生物技术研究所(IMBA)科学主任Josef Penninge

阿斯利康抗癌药Faslodex(氟维司群)治疗HR+晚期乳腺癌疗效显著优于Arimidex(阿那曲唑)

英国制药巨头阿斯利康(AstraZeneca)近日公布了抗癌药Faslodex 500mg注射液(fulvestrant,氟维司群)一项乳腺癌III期临床研究(FALCON)的积极数据。该研究是一项随机、双盲、多中心III期研究,在既往未接受任何激素疗法治疗的激素受体阳性(HR+)局部晚期或转移性乳腺癌绝经后女性患者中开展,将Faslodex 500mg注射液与该公司的抗癌药Arimidex

Baidu
map
Baidu
map
Baidu
map